In Reply We appreciate the interest in our recently published article. We thank Tang et al for their careful review of our meta-analysis of 24 randomized clinical trials that assessed the incidence of cardiovascular events with the addition of androgen receptor–signaling inhibitors to standard of care in locally advanced and metastatic prostate cancer.